by Elena Iemma | Jan 26, 2021 | Events, Webinars
The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products. EpiVax CEO/CSO, Annie De Groot, presented an update on EpiVax’s...
by Annie De Groot | Jan 2, 2019 | Events
4th European Workshop on Protein Aggregation and Immunogenicity Monday, January 28 – Tuesday, January 29 Austria Trend Comfort Hotel Salzburg West Bundesstraße 4 5073 Salzburg-Wals, Austria Thank you to everyone who attended EpiVax’s presentation at the...
by Sarah Moniz | Jun 13, 2018 | News
NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...
